Literature DB >> 25630229

Salivary gland dysfunction after radioactive iodine (I-131) therapy in patients following total thyroidectomy: emphasis on radioactive iodine therapy dose.

Han Na Lee1, Ji Young An1, Kyung Mi Lee1, Eui Jong Kim2, Woo Suk Choi1, Deog Yoon Kim3.   

Abstract

PURPOSE: The purpose of this study was to retrospectively evaluate symptoms, images of salivary gland dysfunction, and related clinical factors in thyroid cancer patients with total thyroidectomy followed by radioiodine therapy (RIT).
METHODS: We included 164 patients who underwent thyroid ultrasonography or contrast-enhanced neck computed tomography more than 6 months later after RIT. Correlation between subjective symptoms and various RIT doses was also evaluated.
RESULTS: Swelling and decreased salivary volume were the most common symptoms and images. RIT dose was the only factor with a positive correlation (P<.001).
CONCLUSION: The dose of RIT should be carefully determined to minimize gland dysfunction.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Radiation sialadenitis; Radioiodine therapy; Salivary gland dysfunction; Total thyroidectomy

Mesh:

Substances:

Year:  2015        PMID: 25630229     DOI: 10.1016/j.clinimag.2014.12.018

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  6 in total

1.  Risk Factors of 131I-Induced Salivary Gland Damage in Thyroid Cancer Patients.

Authors:  Brynn Hollingsworth; Leigha Senter; Xiaoli Zhang; Guy N Brock; Wael Jarjour; Rebecca Nagy; Pamela Brock; Kevin R Coombes; Richard T Kloos; Matthew D Ringel; Jennifer Sipos; Ilene Lattimer; Ricardo Carrau; Sissy M Jhiang
Journal:  J Clin Endocrinol Metab       Date:  2016-08-17       Impact factor: 5.958

2.  Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors.

Authors:  Ruba Riachy; Nisrine Ghazal; Mohamad B Haidar; Ahmad Elamine; Mona P Nasrallah
Journal:  Int J Endocrinol       Date:  2020-08-04       Impact factor: 3.257

3.  Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials.

Authors:  Arunrat Auttara-Atthakorn; Jaruwan Sungmala; Thunyarat Anothaisintawee; Sirimon Reutrakul; Chutintorn Sriphrapradang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-29       Impact factor: 6.055

4.  Optimal administration time of vitamin C after 131I therapy in differentiated thyroid cancer based on propensity score matching.

Authors:  Ye Liu; Yuhua Wang; Wanchun Zhang
Journal:  Front Surg       Date:  2022-09-22

Review 5.  Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand?

Authors:  Marios Adramerinas; Dimitrios Andreadis; Konstantinos Vahtsevanos; Athanasios Poulopoulos; Kalliopi Pazaitou-Panayiotou
Journal:  Hormones (Athens)       Date:  2021-06-18       Impact factor: 2.885

6.  Ultrasonography Echotexture as a surrogate for Sialadenitis secondary to 131I Radioiodine Therapy for differentiated Thyroid Cancer: a review and metaanalysis.

Authors:  Graziele Aparecida Simões Lima; Rossana Verónica Mendoza López; Gislaine Aparecida Ozório; Ricardo Miguel Costa de Freitas; Jose Willegaignon; Marcelo Tatit Sapienza; Maria Christina Chammas; George Barberio Coura-Filho
Journal:  Clinics (Sao Paulo)       Date:  2020-10-19       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.